Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM). Issue 2 (December 2015) - Lapointe, Réjean; Jamal, Rahima; van Kempen, Leon; Thebault, Pamela; Belanger, Karl; Friedmann, Jennifer; Ayoub, Jean-Pierre; Cocolakis, Eftihia; Kazemi, Shirin; Dionne, Jeanne; Lambert, Caroline; Le, Huy; et al.